. . . . . . . "[We conducted a phase I/II clinical study in which patients with recurrent/refractory human epidermal growth factor receptor 2 (HER2) -positive sarcoma received escalating doses (1 \uFFFD 10(4)/m(2) to 1 \uFFFD 10(8)/m(2)) of T cells expressing an HER2-specific chimeric antigen receptor with a CD28.? signaling domain (HER2-CAR T cells).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:11:51+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .